Renal Transplantation

Introduction {#s0005}
============

Transplantation has proven to be the best therapy for end-stage renal disease (ESRD), being superior to maintenance dialysis therapy with better quality of life and lower mortality risk [@b0005]. The impact of glomerulonephritis (GN) on graft outcome is not fully understood [@b0010].

GN has been reported to recur in renal grafts at different rates depending on histological type [@b0015]. Impairment of graft function and even loss has mostly been reported with recurrent GN [@b0020]. Exact diagnosis of GN before transplantation is not easy, as most of the patients present with ESRD without an available histological diagnosis for varying reasons. Thus, most reported diagnoses of GN are based on clinical judgement rather than histological evidence, leading to an incorrect estimation of the true incidence of GN [@b0025]. Another problem is the difficultly in differentiating between GN histological findings and calcineurin-inhibitor nephrotoxicity and chronic allograft nephropathy [@b0030].

Recurrent GN is clinically relevant, as it can result in long-term graft loss; it was reported to be the third most common cause of graft loss during the 10-year period after transplantation. The negative impact of recurrent GN increased from 0.6% during the first year after transplantation to 8.4% after 10 years [@b0015]. In the present study, we analysed the incidence of different types of GN reported after transplantation, potential precipitating factors, and their potential risk on graft survival.

Patients and methods {#s0010}
====================

This study comprised 2000 transplant recipients who received their grafts between March 1976 and February 2010 at Mansoura Urology and Nephrology Center. In all, 1648 patients received their grafts from related donors, while the other 352 received their grafts from unrelated donors. Among the unrelated group, 122 were spouses. The procedures were approved by the ethics committee of human experimentation in our centre and in accordance with the Helsinki declaration of 1975.

Exclusion criteria included: couples with historical positive lymphocytotoxic cross match, recent malignancy, addiction, psychiatric disorders, type I diabetes mellitus, significant extra-renal organ failure (pulmonary, hepatic, or cardiac), other exclusion criteria for donors included: unwilling donors, diabetes mellitus, hypertension, positive hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, anti-HIV and anti-cytomegalovirus (CMV) IgM antibodies. All clinical records of all kidney transplant recipients were entered prospectively in our computer network transplant database.

Study design {#s0015}
------------

This is a retrospective study in which the patients were divided according to graft biopsy results into two groups: Group I (No GN) included patients who did not have post-transplantation GN (PTGN). Group II (PTGN) included patients who developed PTGN. This group was further divided according to the nature of GN into:•*de novo* GN, which included patients who did not have biopsy confirmed GN before transplantation or had a different type of GN than the one discovered after transplantation;•recurrent GN, which included patients with PTGN of the same histopathological type as that before transplantation;•transplant glomerulopathy, which included patients with glomerular injury with unique pathological and pathogenic entity distinct from other forms of chronic allograft injury.

GN management was according to the international protocols valid at the time of graft biopsy. The protocol table is provided in the Appendix.

Statistical analysis {#s0020}
--------------------

Qualitative data are presented in cross tabulation and quantitative data are presented as the mean (standard deviation, SD). Univariate analyses were used for initial evaluation of differences using the chi-square and Fisher's exact tests. A *P* \< 0.05 was considered to indicate statistical significance. Graft and patient survival rates were evaluated by means of Kaplan--Meier survival curves. Significant variables in the univariate analysis were further analysed by multivariate analysis to determine those that acted independently (*P* \< 0.05) using the Cox model. All analyses were carried out using the computer package SPSS for windows, release 16 SPSS Inc. Chicago, IL, USA.

Results {#s0025}
=======

The patients' demographic data show that there was a higher frequency of PTGN in younger recipients. Focal segmental glomerulosclerosis (FSGS) was the predominant original cause of ESRD among group II, whereas in group I chronic pyelonephritis was the most common original kidney disease ([Table 1](#t0010){ref-type="table"}).

Most of our ESRD recipients with GN were children, so parents constituted most of the donors in group II. The donors' gender was comparable in both groups. The percentage of parent donors was higher in group I. The incidence of recurrent GN was higher in the first 3 months after transplant compared with *de novo* GN. While transplant glomerulopathy incidence was higher than recurrent and *de novo* GN at 5 years after transplantation (*P* = 0.039; [Fig. 1](#f0005){ref-type="fig"}).

[Table 2](#t0040){ref-type="table"} shows that either *de novo* GN or transplant glomerulopathy most commonly occurred in patients with uncertain original kidney disease. Recurrent FSGS was the most common histopathological type of GN, accounting for 44.4% of recurrent and 6.7% of *de novo* GNs, membrano-proliferative glomerulonephritis (MPGN) was the second most common histological type, systemic lupus GN was the most common original kidney disease associated with transplant glomerulopathy after transplantation. There were no significant differences for induction immunosuppression and primary immunosuppression in patients who had PTGN (*P* = 0.881, *P* = 0.197, respectively). Acute cellular rejection episodes were higher, but not significantly so, among patients who developed *de novo* GN (*P* = 0.566). Chronic rejection was significantly higher among patients who developed transplant glomerulopathy (*P* \< 0.001). A significantly higher percentage of recipients had post-transplantation hypertension in group II than in group I. The percentage of other medical complications was comparable between the groups ([Table 3](#t0020){ref-type="table"}).

[Fig. 2](#f0010){ref-type="fig"} shows that long-term graft survival was significantly lower in group II vs group I within the first 2 years after transplantation (*P* \< 0.001). While recurrent GN negatively impacted graft survival significantly compared with *de novo* and transplant glomerulopathy in the first 5 years. These differences equalised after 10 years (*P* = 0.067). There were significant differences between groups I and II for patient survival (*P* = 0.048). *De novo* GN and transplant glomerulopathy had a significantly negative impact on patient survival compared with recurrent GN and group I (*P* = 0.005; [Fig. 3](#f0015){ref-type="fig"}).

[Table 4](#t0025){ref-type="table"} shows Cox multivariate analysis for the identification of possible independent risk factors for the development of PTGN, which showed that middle-age donors (aged 31--40 years) carried 1.76 risk (95% CI 1.04--3) compared with other donor grafts (*P* = 0.035). A Sirolimus-based immunosuppression protocol was associated with 4.6-fold risk (95% CI 2.14--10) for the development of PTGN (*P* \< 0.001). While, a different blood group between the donor and recipient carried a favourable significant delay in the development of PTGN (*P* = 0.005).

[Table 5](#t0030){ref-type="table"} shows the Cox multivariate analysis for risk factors for graft loss, which showed that transplant recipients aged 40--50 years have a 1.82-fold risk (95% CI 1.24--2.67) of losing their graft after 10 years vs the other transplant recipients (*P* = 0.002). Induction therapy with polyclonal antibody (anti-thymocyte globulin, ATG) doubled the risk of graft loss \[hazard ratio (HR) 1.99, 95% CI 1.53--2.6\] than induction therapy with monoclonal antibodies (*P* \< 0.001). Acute rejection episodes carry an independent negative impact on long-term graft survival. One episode of acute rejection had a 1.35-fold risk (95% CI 1--1.8) of graft loss (*P* = 0.049). Two or more acute rejection episodes increased the risk of graft loss by 1.97 times (95% CI 1.45--2.7) (*P* \< 0.001). Development of chronic rejection increased the risk to 2.41 times (95% CI 1.9--3) of long-term graft loss (*P* \< 0.001). *De novo* GN had an independent negative risk on long-term graft loss of 3.33-times (95% CI 1.5--7.4) that of the other histopathological types (*P* = 0.003). Middle-aged donor grafts carried a favourable significant effect on graft survival (HR 0.77, 95% CI 0.61--0.99). Patients receiving their grafts from their offspring were at less risk of losing their graft after 10 years (HR 0.74, 95% CI 0.56--0.97) (*P* = 0.028). A different blood group had a favourable effect on graft survival (HR 0.75, 95% CI 0.59--0.95) (*P* = 0.016).

Discussion {#s0030}
==========

The frequency of graft--antigen recognition and impact of alloimmune injury have been significantly reduced with the evolution of immunosuppression, which has improved post-transplantation long-term survival [@b0035]. Hume et al. [@b0040] reported that transplanted patients are not invulnerable from being at risk of GN, in all its forms, in the graft. The frequency of PTGN reached 40% and the cumulative probability increases with transplantation time [@b0045]. A possible link between HCV infection and glomerulopathy has previously been reported [@b0050]. In our present cohort, most of the donors among the PTGN group were parents, which supports the possible genetic predisposition reported previously [@b0055]. GN has been found to be associated with mutations in several genes and the coding of several proteins that encode for podocytes function [@b0055]. It has been reported that recurrent GN represents 70% of PTGN cases and IgA nephropathy was the most common histological form [@b0060]. In our present series, recurrent FSGS was the predominated histopathological type, followed by MPGN and this was statistically significant (*P* \< 0.001). The low incidence of reported IgA in our present series may be explained by the delayed introduction of immunofluorescence studies in our graft biopsies. Our present data are consistent with a Canadian study, which reported a higher frequency of recurrent FSGS compared with patients with other disorders [@b0005]. The incidence of PTGN is higher in patients known to have chronic kidney disease than in the normal population [@b0065], [@b0070]. *De novo* GN is associated with frequent episodes of acute rejection, while chronic rejection overlapped with transplant glomerulopathy. Ibrahim et al. [@b0075] reported the possibility of an acute rejection association with PTGN and that the frequency of PTGN is not affected by early steroid withdrawal.

Multivariate analysis for the risk of developing PTGN revealed two independent risk factors. Renal grafts from middle-aged donors carried a 1.8-fold higher risk of PTGN than grafts from other donor age groups; this may be explained by the fact that autoimmune diseases are more prevalent in the middle-aged population. Furthermore, the most common histopathological GN type in our present cohort was FSGS and it was documented that one of the major risk factors of recurrence of FSGS was renal ischaemic injury [@b0080], combined with the genetic susceptibility transferred with the graft from the parent donor [@b0055]. A sirolimus-based immunosuppression protocol was associated with a 4.6-fold higher risk of developing GN after transplantation. Our present data are consistent with reports documenting the immunosuppressive therapy role: cyclosporine was reported to cause renal injury including FSGS and sirolimus toxicity can lead to tubular injury and FSGS in patients with a genetic susceptibility [@b0085]. Recurrent GN is associated with worse graft outcome than *de novo* GN or transplant glomerulopathy. The present data highlight the importance of PTGN as a cause of graft loss in renal transplant recipients and it is associated with a dramatic reduction in graft survival [@b0025]. Graft prognosis depends on the severity and histological form of GN, as well as whether the GN is recurrent or *de novo* [@b0090], [@b0095]. There is no effective treatment for PTGN, intensive plasma exchange or Rituximab may be of benefit in some cases of FSGS but is of no benefit in many instances [@b0100]. Efforts should be made to outline a standard approach to define risk factors of different forms of this serious disease affecting the survival of the graft that will lead to more specific therapy [@b0105].

In conclusion, from our present results GN as a cause of renal failure represents a medical dilemma that may persist after transplantation. Early identification and understanding of the ongoing precipitating mechanisms may change our monitoring and immunosuppression strategies and improve long-term graft outcome.
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Appendix A {#s0050}
==========

Treatment strategies for different types of GN.TreatmentClinically relevant^∗^ recurrent risk^†^, %Risk of graft loss due to recurrence 5--10 years after transplantation^†^, %Prevention/treatment strategiesIgAN13--462--16ACEI and/or ARB for patients with proteinuria ± renal impairment due to recurrent IgAN [@b0110], [@b0115]FSGS20--5013--20Avoid living donors for patients with history of rapid graft loss from recurrence [@b0120]Pre-emptive perioperative plasmapheresis (PP) for 2 weeks for patients with high risk of recurrence [@b0125], [@b0130]Chronic PP with or without cyclophosphamide or cyclosporine for patients with relapse after initial course of PP [@b0135], [@b0140], [@b0145]Avoid omission of calcineurin inhibitors in sirolimus-based immunosuppressive regimen [@b0150], [@b0155]Avoid induction therapy [@b0160], [@b0165]MPGN Type I20--25≈15No effective preventive or treatment measures Type II80--10015--30Exclude secondary causesMembranous nephropathy10--3010--15No effective preventive or treatment measuresExclude secondary causesANCA-associated glomerulonephritis≈176--8Defer transplant till disease inactive [@b0170]Cyclophosamide for recurrence [@b0170], [@b0175]Combine therapy with PP, cyclophosphamide ± i.v. immunoglobulin for recurrence with high titre of ANCA and cellular crescents in renal biopsies [@b0175], [@b0185]SLE2--92--4Defer transplant until disease inactive [@b0190], [@b0195]Consider mycophenolate mofetil for recurrence [@b0200], [@b0205]Anti-GBMRareRareDefer transplant until disease inactiveCombine therapy with PP/immunoabsorption and cyclophosphamide for recurrence with high anti-GBM titre and cellular crescents in renal biopsies [@b0180], [@b0210]^∗^Clinically relevant refers to patients with clinical symptoms of proteinuria/haematuria/renal impairment.^†^% of transplanted patients. IgAN, recurrent IgA nephropathy; SLE, systemic lupus erythematosus; ACEI, angiotensin-converting enzyme inhibitor; ANCA, anti-neutrophil cytoplasmic autoantibody; GBM, glomerular basement membrane.
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![Incidence of GN after transplantation. Post-transplantation incidence of recurrent GN (solid line) and *de novo* GN (dashed line) were significantly higher than transplant glomerulopathy (pointed line) (*P* = 0.039).](gr1){#f0005}

![Graft survival of the recipients who did not develop PTGN vs recipients who developed PTGN. (A) Graft survival in the recipients who developed PTGN (dashed line) was comparable to those with no PTGN (solid line) in the first 2 years. Thereafter, there was a significant drop in graft survival in the group of recipients who had PTGN vs those who did not develop PTGN (*P* \< 0.001). (B) Graft survival in the recipients who developed *de novo* GN (dashed line) and transplant glomerulopathy (pointed line) was comparable to those who did not develop PTGN (solid bold line) in the first 2 years (*P* = 0.067). While there was a significant drop in graft survival in recipients with recurrent GN (solid thin line) vs other groups in the first 2 years. Thereafter, there was a significant drop in graft survival in the group of recipients who had PTGN (whatever the type) vs those who did not develop PTGN (*P* = 0.001).](gr2){#f0010}

![Patient survival of the recipients who did not develop GN vs recipients who developed PTGN. (A) Patient survival in the recipients who developed PTGN (dashed line) was comparable to those with no PTGN (solid line) in the first 5 years. Thereafter, there was a significant drop in patient survival in the group of recipients who had PTGN vs those who did not develop PTGN (*P* = 0.048). (B) patient survival in the recipients who developed PTGN (whatever the cause) was comparable to those who did not develop PTGN in the first 5 years. Thereafter, there was a significant drop in patient survival in the group of recipients who had *de novo* GN (dashed line) and transplant glomerulopathy (solid line) vs those who did not develop PTGN (*P* = 0.005).](gr3){#f0015}

###### 

The demographic characteristics of the 2000 renal transplants.

  Characteristic                   No GN           PTGN            *P*
  -------------------------------- --------------- --------------- -------
  Number of patients               1897            103             
  Mean (SD) recipient age, years   29.84 (10.62)   27.56 (10.55)   0.034
  *N (%):*                                                         
   Recipients age range, years                                     
    \<20                           363 (19.1)      30 (29.1)       0.042
    20--30                         595 (31.4)      31 (30.1)       
    30--40                         572 (30.2)      28 (27.2)       
    40--50                         295 (15.6)      11 (10.7)       
    \>50                           72 (3.8)        3 (2.9)         
   Sex                                                             
    Male                           1413 (74.5)     78 (75.7)       0.778
    Female                         484 (25.5)      25 (24.3)       
   Pre-transplant hypertension                                     
    No                             799 (42.1)      42 (40.7)       0.788
    Yes                            1098 (57.9)     61 (59.3)       
   Type of blood transfusion                                       
    Donor specific                 11 (0.6)        1 (0.97)        0.273
    Third party                    852 (44.9)      54 (52.4)       
    No transfusion                 1034 (54.5)     48 (46.6)       
   Type of dialysis                                                
    Pre-emptive                    79 (4.2)        1 (0.9)         0.280
    Haemodialysis                  1797 (94.7)     102 (99.1)      
    Peritoneal dialysis            21 (1.1)        --              
                                                                   
  Mean (SD) donors age, years      35.47 (10.1)    36 (10.7)       0.605
  *N (%)*                                                          
   Donors age range, years                                         
    \<30                           745 (39.3)      37 (35.9)       0.789
    30--40                         604 (31.8)      33 (32)         
    40--50                         379 (20)        20 (19.4)       
    \>50                           169 (8.9)       13 (12.6)       
   Donors sex                                                      
    Male                           903 (47.6)      50 (48.5)       0.881
    Female                         994 (52.4)      53 (51.5)       
   Consanguinity                                                   
    Parent                         542 (28.6)      35 (34)         0.238
    Sibling                        890 (46.9)      46 (44.7)       0.655
    Off-spring                     29 (1.5)        1 (0.97)        0.650
    Emotionally related            116 (6.1)       6 (5.8)         0.905
    Other relative                 101 (5.3)       4 (3.9)         0.523
    Unrelated                      219 (11.5)      11 (10.7)       0.789
   Blood groups, recipient/donor                                   
    Same                           1527 (80.5)     80 (77.7)       0.482
    Different (but compatible)     370 (19.5)      23 (22.3)       
   HLA Class I mismatch                                            
    Zero                           148 (7.8)       6 (5.8)         0.181
    One                            215 (11.3)      16 (15.5)       
    Two                            952 (50)        58 (56.3)       
    Three                          294 (15.5)      16 (15.5)       
    Four                           129 (6.8)       4 (3.9)         
    Undetermined                   159 (8.4)       3 (2.9)         
   HLA Class II (DR) mismatch                                      
    Zero                           195 (10.3)      10 (9.7)        0.452
    One                            1656 (87.3)     93 (90.3)       
    Two                            2 (0.1)         --              
    Undetermined                   44 (2.3)        --              
   Transplant received                                             
    First                          1821 (96)       101 (98.1)      0.562
    Second                         73 (3.8)        2 (1.9)         
    Third                          3 (0.2)         --              
   Ischaemia time, min                                             
    \<30                           217 (11.4)      9 (8.7)         0.672
    30--60                         1378 (72.6)     76 (73.8)       
    \>60                           302 (15.9)      18 (17.5)       
   Time to diuresis                                                
    Immediate                      1745 (92)       94 (91.3)       0.792
    Delayed                        152 (8)         9 (8.7)         
   Number of renal arteries                                        
    One                            1681 (88.6)     95 (92.2)       0.975
    Two                            193 (10.2)      8 (7.8)         
    Three                          21 (1.1)        --              
    Four                           1 (0.05)        --              
    Five                           1 (0.05)        --              

HLA, human leucocyte antigen.

###### 

Original kidney disease and immunosuppression of patients with PTGN.

                                          Recurrent GN, *n* (%)   *De novo* GN, *n* (%)   Transplant glomerulopathy, *n* (%)   *P*
  --------------------------------------- ----------------------- ----------------------- ------------------------------------ ---------
  Number of patients                      18                      15                      70                                   
                                                                                                                               
  Patients with pre-transplant GN                                                                                              
   Mesangial                              1 (5.6)                 --                      --                                   \<0.001
   Membranous nephropathy                 1 (5.6)                 --                      1 (1.4)                              
   FSGS                                   8 (44.4)                1 (6.7)                 5 (7.1)                              
   Membrano-proliferative                 4 (22.2)                2 (13.3)                2 (2.8)                              
   Crescentic GN                          1 (5.6)                 1 (6.7)                 --                                   
   Hereditary nephritis                   --                      2 (13.3)                2 (2.8)                              
   Amyloidosis                            2 (11.1)                --                      2 (2.8)                              
   SLE[⁎](#tblfn1){ref-type="table-fn"}   1 (5.6)                 1 (6.7)                 8 (11.4)                             
                                                                                                                               
  Patients with no pre-transplant GN                                                                                           
   Polycystic kidney                      --                      1 (6.7)                 1 (1.4)                              \<0.001
   Hypoplasia                             --                      --                      2 (2.8)                              
   Chronic pyelonephritis                 --                      1 (6.7)                 6 (8.6)                              
   Nephrosclerosis                        --                      --                      2 (2.8)                              
   ESRD                                   --                      3 (20)                  27 (38.6)                            
   Congenital                             --                      --                      1 (1.4)                              
   Obstructive uropathy                   --                      --                      1 (1.4)                              
   Inapplicable                           --                      3 (20)                  10 (14.3)                            
                                                                                                                               
  Induction therapy                                                                                                            
   Polyclonal antibodies                  2 (11.1)                3 (20)                  8 (11.4)                             0.881
   Monoclonal antibodies                  5 (27.8)                4 (26.7)                15 (21.5)                            
   No induction                           11 (61.1)               8 (53.3)                47 (67.1)                            
                                                                                                                               
  Primary immunosuppression                                                                                                    
   Conventional based                     2 (11.1)                2 (13.3)                22 (31.4)                            0.197
   Triple based                           14 (77.7)               9 (60)                  38 (54.4)                            
   Tacrolimus based                       1 (5.6)                 --                      --                                   
   Sirolimus based                        1 (5.6)                 3 (20)                  8 (11.4)                             
   Steroid avoidance                      --                      1 (6.7)                 1 (1.4)                              
   Alemtuzumab                            --                      --                      1 (11.4)                             

Systemic lupus erythematosus.

###### 

Medical complications after transplantation in patients with PTGN.

                            Recurrent GN, *n* (%)   *De novo* GN, *n* (%)   Transplant glomerulopathy, *n* (%)   *P*
  ------------------------- ----------------------- ----------------------- ------------------------------------ ---------
  Number of patients        18                      15                      70                                   
  Acute tubular necrosis                                                                                         
   No                       16 (88.9)               15 (100)                67 (95.7)                            0.310
   Yes                      2 (11.1)                --                      3 (4.3)                              
                                                                                                                 
  Hypertension                                                                                                   
   No                       6 (33.3)                2 (13.3)                18 (25.7)                            0.415
   Yes                      12 (66.7)               13 (86.7)               52 (74.3)                            
                                                                                                                 
  Post-transplantation DM                                                                                        
   No                       16 (88.9)               9 (60)                  56 (80)                              0.116
   Yes                      2 (11.1)                6 (40)                  14 (20)                              
                                                                                                                 
  Medical infection                                                                                              
   No                       14 (77.8)               13 (86.7)               47 (67.1)                            0.258
   Yes                      4 (22.2)                2 (13.3)                23 (32.9)                            
                                                                                                                 
  Hepatic impairment                                                                                             
   No                       17 (94.4)               13 (86.7)               64 (91.4)                            0.730
   Yes                      1 (5.6)                 2 (13.3)                6 (8.6)                              
                                                                                                                 
  Acute rejection                                                                                                
   No                       12 (66.7)               7 (46.7)                36 (51.4)                            0.566
   Acute cellular           6 (33.3)                8 (53.3)                31 (44.3)                            
   Acute vascular           --                      --                      3 (4.3)                              
                                                                                                                 
  Chronic rejection                                                                                              
   No                       16 (88.9)               14 (93.3)               36 (51.4)                            \<0.001
   Yes                      2 (11.1)                1 (6.7)                 34 (48.6)                            
                                                                                                                 
  Malignancy                                                                                                     
   No                       17 (94.4)               13 (86.7)               68 (97.1)                            0.228
   Yes                      1 (5.6)                 2 (13.3)                2 (2.9)                              

###### 

Multivariate analysis of the risk factors for developing PTGN.

                                      Regression estimate (B)   Relative risk (95% CI), Exp B   *P*
  ----------------------------------- ------------------------- ------------------------------- ---------
  Recipient age, years                                                                          
   \<20                               --                        1                               
   20--30                             --0.929                   0.40 (0.152--1.03)              0.057
   31--40                             --0.512                   0.60 (0.26--1.39)               0.231
   41--50                             --0.330                   0.72 (0.25--2.1)                0.540
   \>50                               0.793                     0.45 (0.039--5.23)              0.525
                                                                                                
  Original kidney disease                                                                       
   No GN                              --                        1                               
   GN                                 0.015                     1.01 (0.566--1.821)             0.959
                                                                                                
  Donor age, years                                                                              
   \<30                               --                        1                               
   31--40                             0.570                     1.76 (1.04--3)                  0.035
   41--50                             0.602                     1.82 (0.977--3.41)              0.059
   \>50                               0.289                     1.33 (0.657--2.71)              0.424
                                                                                                
  Recipient sex match                                                                           
   Male--male                         --                        1                               
   Male--female                       --0.228                   0.796 (0.319--1.98)             0.625
   Female--male                       0.397                     1.48 (0.743--2.97)              0.263
   Female--female                     0.451                     1.57 (0.576--4.27)              0.378
                                                                                                
  Consanguinity                                                                                 
   Parent                             --                        1                               
   Sibling                            0.518                     1.67 (0.47--5.97)               0.424
   Off-spring                         1.261                     3.52 (0.1--125)                 0.489
   Other relative                     0.898                     2.45 (0.57--10.6)               0.231
   Unrelated                          1.220                     3.38 (0.82--14.1)               0.093
                                                                                                
  Donor/recipient blood group match                                                             
   Same                               --                        1                               
   Different                          --0.869                   0.42 (0.23--0.77)               0.005
                                                                                                
  Blood transfusion                                                                             
   No                                 --                        1                               
   Yes                                --0.451                   0.64 (0.39--1.05)               0.075
                                                                                                
  Ischaemia time, min                                                                           
   \<30                               --                        1                               
   30--60                             --0.711                   0.491 (0.194--1.27)             0.134
   \>60                               --0.437                   0.65 (0.196--2.13)              0.473
                                                                                                
  Time to diuresis                                                                              
   Immediate                          --                        1                               
   Delayed                            0.473                     1.60 (0.58--4.47)               0.366
                                                                                                
  Induction therapy                                                                             
   No                                 --                        1                               
   Polyclonal                         0.217                     1.24 (0.361--4.28)              0.731
   Monoclonal                         --0.271                   0.763 (0.262--2.22)             0.619
                                                                                                
  Maintenance immunosuppression                                                                 
   Conventional                       --                        1                               
   CsA based                          0.278                     1.32 (0.74--2.34)               0.343
   Tacrolimus                         1.855                     6.39 (0.76--54)                 0.089
   Sirolimus                          1.536                     4.64 (2.14--10)                 \<0.001
   Steroid avoidance                  0.589                     1.80 (0.386--8.4)               0.454
                                                                                                
  Steroids in first 3 months, g                                                                 
   \<5                                --                        1                               
   5--10                              −0.088                    0.92 (0.45--1.89)               0.812
   \>10                               0.631                     1.87 (0.78--4.5)                0.158

CsA, cyclosporin A.

###### 

Multivariate analysis of the risk factors of graft survival.

                                      Regression estimate (B)   Relative risk (95% CI), Exp B   *P*
  ----------------------------------- ------------------------- ------------------------------- ---------
  Recipient age, years                                                                          
   \<20                               --                        1                               
   20--30                             0.070                     1.07 (0.80--1.44)               0.640
   31--40                             0.262                     1.30 (0.93--1.81)               0.120
   41--50                             0.601                     1.82 (1.24--2.67)               0.002
   \>50                               0.562                     1.75 (0.95--3.22)               0.070
                                                                                                
  Original kidney disease                                                                       
   No GN                              --                        1                               
   GN                                 --0.071                   0.93 (0.68--1.27)               0.652
                                                                                                
  Donor age, years                                                                              
   \<30                               --                        1                               
   31--40                             --0.257                   0.77 (0.61--0.99)               0.038
   41--50                             0.245                     1.27 (0.94--1.74)               0.118
   \>50                               0.109                     1.12 (0.73--1.71)               0.615
                                                                                                
  Recipient sex match                                                                           
   Male--male                         --                        1                               
   Male--female                       0.127                     1.14 (0.82--1.56)               0.439
   Female-- male                      0.018                     1.02 (0.67--1.54)               0.931
   Female--female                     0.059                     1.06 (0.78--1.44)               0.705
                                                                                                
  Consanguinity                                                                                 
   Parent                             --                        1                               
   Sibling                            --0.036                   0.97 (0.65--1.43)               0.858
   Off-spring                         --0.303                   0.74 (0.56--0.97)               0.028
   Other relative                     0.771                     2.16 (0.95--4.92)               0.066
   Unrelated                          0.249                     1.28 (0.83--1.99)               0.266
                                                                                                
  Donor/recipient blood group match                                                             
   Same                               --                        1                               
   Different                          --0.294                   0.75 (0.59--0.95)               0.016
                                                                                                
  Blood transfusion                                                                             
   No                                 --                        1                               
   Donor specific                     --0.027                   0.97 (0.79--1.2)                0.800
   Third party                        --0.077                   0.93 (0.36--2.4)                0.873
                                                                                                
  Ischaemia time, min                                                                           
   \<30                               --                        1                               
   30--60                             0.205                     1.23 (0.97--1.5)                0.089
   \>60                               0.327                     1.39 (0.94--2.05)               0.103
                                                                                                
  Time to diuresis                                                                              
   Immediate                          --                        1                               
   Delayed                            0.140                     1.15 (0.83--1.6)                0.395
                                                                                                
  Induction therapy                                                                             
   No                                 --                        1                               
   Polyclonal                         0.688                     1.99 (1.53--2.6)                \<0.001
   Monoclonal                         --0.448                   0.64 (0.35--1.18)               0.151
                                                                                                
  Maintenance immunosuppression                                                                 
   Conventional                       --                        1                               
   CsA based                          0.116                     1.12 (0.27--4.6)                0.872
   Tacrolimus                         --0.142                   0.87 (0.21--3.5)                0.843
                                                                                                
  Steroids in first 3 months, g                                                                 
   \<5                                --                        1                               
   5--10                              --0.149                   0.86 (0.68--1.1)                0.216
   \>10                               --0.044                   0.96 (0.69--1.3)                0.786
                                                                                                
  Rejection                                                                                     
   No                                 --                        1                               
   One acute rejection                0.301                     1.35 (1--1.8)                   0.049
   ⩾two acute rejections              0.681                     1.97 (1.45--2.7)                \<0.001
   Chronic rejection                  0.878                     2.41 (1.9--3)                   \<0.001
                                                                                                
  PTGN                                                                                          
   No                                 --                        1                               
   Recurrent GN                       --0.226                   0.79 (0.56--1.13)               0.207
   *de novo* GN                       1.205                     3.33 (1.5--7.4)                 0.003
   Transplant GN                      0.530                     1.69 (0.77--3.76)               0.191
